Point mutations from exome-sequencing. Point mutations, sequencing reads and mutation frequency in tamoxifen-resistant cells (Resistant Reference Reads, Resistant Variant Reads, Resistant Variant Frequency) compared to their parental cell lines (Parental Reference Reads, Parental Variant Reads, Parental Variant Frequency) revealed by exome-sequencing. Sample ID, chromosome, position, reference and variant base, affected gene, effect, effect impact, and p-values are also indicated. (XLSX 250Â kb
Figure S5. ddPCR validation of mutations identified by MammaSeq⢠is indicated along with mutant al...
Figure S2. Mean sequencing read depth for (A.) the 46 solid tumor cohort. (B.) isolated mononuclear ...
Figure S3. DNA copy number alterations in the IBC cohort. The genes with DNA copy number alterations...
Drug testing and molecular profiling reveal sensitivity and co-resistance networks in MCF-7 Tam1. (A...
Drug testing and molecular profiling reveal sensitivity and co-resistance networks in ZR-75-1 Tam1 a...
List with all genes (exome-wide) presenting a PDAV in at least two BC patients and the number of con...
List with PDAVs detected in 54âBC patients located in genes linked to (hereditary) cancer and/or h...
Figure S4. Tumor mutational burden across all samples in the 46 solid tumor cohort. (A.) Total detec...
Types and number of variants detected (exome- and CAGP-wide) before and after variant filtration in ...
BC patients vs. controls variant types enrichment in exome- and CAGP-wide. (XLSX 10 kb
Breast cancer (BC) patients considered for the study, their age at diagnosis and the number of affec...
PDAVs found in the CAPG of the 120 control samples and their occurrence in the general population. (...
Figure S2. Mutual exclusivity analysis in TCGA breast invasive carcinoma cohort. OncoPrints showing ...
Sample preparation, sequencing, analysis and variant validation workflow. (TIF 2207 kb
Figure S1. Comparison of somatic mutation frequency between IBC and non-IBC in four subgroups. (a) T...
Figure S5. ddPCR validation of mutations identified by MammaSeq⢠is indicated along with mutant al...
Figure S2. Mean sequencing read depth for (A.) the 46 solid tumor cohort. (B.) isolated mononuclear ...
Figure S3. DNA copy number alterations in the IBC cohort. The genes with DNA copy number alterations...
Drug testing and molecular profiling reveal sensitivity and co-resistance networks in MCF-7 Tam1. (A...
Drug testing and molecular profiling reveal sensitivity and co-resistance networks in ZR-75-1 Tam1 a...
List with all genes (exome-wide) presenting a PDAV in at least two BC patients and the number of con...
List with PDAVs detected in 54âBC patients located in genes linked to (hereditary) cancer and/or h...
Figure S4. Tumor mutational burden across all samples in the 46 solid tumor cohort. (A.) Total detec...
Types and number of variants detected (exome- and CAGP-wide) before and after variant filtration in ...
BC patients vs. controls variant types enrichment in exome- and CAGP-wide. (XLSX 10 kb
Breast cancer (BC) patients considered for the study, their age at diagnosis and the number of affec...
PDAVs found in the CAPG of the 120 control samples and their occurrence in the general population. (...
Figure S2. Mutual exclusivity analysis in TCGA breast invasive carcinoma cohort. OncoPrints showing ...
Sample preparation, sequencing, analysis and variant validation workflow. (TIF 2207 kb
Figure S1. Comparison of somatic mutation frequency between IBC and non-IBC in four subgroups. (a) T...
Figure S5. ddPCR validation of mutations identified by MammaSeq⢠is indicated along with mutant al...
Figure S2. Mean sequencing read depth for (A.) the 46 solid tumor cohort. (B.) isolated mononuclear ...
Figure S3. DNA copy number alterations in the IBC cohort. The genes with DNA copy number alterations...